Liprolog Kwikpen

Insulin lispro, the active ingredient in Liprolog Kwikpen, is a rapid‑acting insulin analog presented as a prefilled pen for subcutaneous use. It is used to lower blood glucose levels in adults and children with Type 1 or Type 2 diabetes mellitus. GNH USA supplies Liprolog Kwikpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Liprolog Kwikpen contains insulin lispro, a rapid‑acting insulin analog that provides prandial glucose control for diabetes mellitus.

- Type 1 diabetes mellitus: improves post‑prandial glucose control and reduces hyperglycaemic excursions. - Type 2 diabetes mellitus: offers rapid insulin coverage for meals, supporting overall glycaemic management. - Insulin pump therapy (as a rapid‑acting bolus insulin): can be used for pump filling to deliver precise mealtime insulin doses.

Adverse reactions may occur with any insulin therapy.

Common Side Effects: - Hypoglycaemia: symptoms of low blood sugar such as shakiness, sweating, or confusion. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase in body weight with chronic use.

Serious or Rare Side Effects: - Severe hypoglycaemia: loss of consciousness or seizures requiring immediate medical attention. - Anaphylactic reaction: hives, difficulty breathing, or throat swelling. - Lipodystrophy: abnormal fat accumulation or loss at injection sites with repeated use.

Careful monitoring and patient education are essential when using rapid‑acting insulin analogs.

- Dose adjustment: regularly monitor blood glucose and adjust insulin dose as needed. - Hypoglycaemia risk: educate patients on recognising and treating low blood sugar promptly. - Renal impairment: consider dose reduction in patients with reduced kidney function. - Pregnancy: use only if the expected benefit justifies the potential risk to the fetus. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin lispro may interact with several medications that affect glucose metabolism.

Major Interactions (Avoid): - Beta‑blockers: can mask hypoglycaemia symptoms. - Monoamine oxidase inhibitors (MAOIs): may potentiate insulin’s glucose‑lowering effect. - Alcohol: enhances risk of hypoglycaemia, especially with fasting.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may increase blood glucose levels. - Corticosteroids: can raise glucose, requiring higher insulin doses. - ACE inhibitors: may affect potassium balance, influencing insulin action. - Oral contraceptives: may alter insulin sensitivity and glucose control.